

Effects of GSK v Teva Ripple after SCOTUS Denies Cert

May 23, 2023

ATTORNEYS

Blau, Ross

Landmon, Chad

PRACTICE AREAS

Intellectual Property

Patents

Chad Landmon, Ross Blau, and Gulrukh Haroon*

Life Sciences IP Review

Axinn partner Chad Landmon and associates Ross Blau and Gulrukh Haroon co-authored the *Life Sciences IP Review* article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."

[Click here](#) to access the publication. A subscription is required.

**Not yet admitted to the New York Bar*